Peter wrote: 
> Although most of these mutants achieved resistance through point mutation or deletion of the target sequence, one HIV mutant escaped RNAi suppression by accumulating mutations outside of the target sequence, thereby creating a new local RNA secondary structure that presumably excluded RISC. These results demonstrate conclusively that any effective RNAi-based antiviral therapy must compensate for the evolutionary potential of the pathogen.

I must ask- how does or can a therapy compensate for the evolutionary potential of the pathogen? Is this just wording or is it actually plausible  to have a manipulated antiviral "compensate"? Can it only be "compensated" by disclaimer: that there might be mutations and morphing of the virus?
 
Wanting to understand better-
Melanie Kirby
 		 	   		  
             ***********************************************
The BEE-L mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software.  For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html

Guidelines for posting to BEE-L can be found at:
http://honeybeeworld.com/bee-l/guidelines.htm